These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

4215 related items for PubMed ID: 15721407

  • 1. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
    Watari H, Todo Y, Takeda M, Ebina Y, Yamamoto R, Sakuragi N.
    Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
    [Abstract] [Full Text] [Related]

  • 2. Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer.
    Fujimoto T, Nanjyo H, Nakamura A, Yokoyama Y, Takano T, Shoji T, Nakahara K, Yamada H, Mizunuma H, Yaegashi N, Sugiyama T, Kurachi H, Sato A, Tanaka T.
    Gynecol Oncol; 2007 Nov; 107(2):253-9. PubMed ID: 17640720
    [Abstract] [Full Text] [Related]

  • 3. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy.
    Nelson G, Randall M, Sutton G, Moore D, Hurteau J, Look K.
    Gynecol Oncol; 1999 Nov; 75(2):211-4. PubMed ID: 10525373
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of postoperative chemotherapy for para-aortic lymph node metastasis of endometrial cancer.
    Takeshima N, Umayahara K, Fujiwara K, Hirai Y, Takizawa K, Hasumi K.
    Gynecol Oncol; 2006 Aug; 102(2):214-7. PubMed ID: 16457876
    [Abstract] [Full Text] [Related]

  • 5. Analysis of FIGO Stage IIIc endometrial cancer patients.
    McMeekin DS, Lashbrook D, Gold M, Johnson G, Walker JL, Mannel R.
    Gynecol Oncol; 2001 May; 81(2):273-8. PubMed ID: 11330962
    [Abstract] [Full Text] [Related]

  • 6. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.
    Aoki Y, Watanabe M, Amikura T, Obata H, Sekine M, Yahata T, Fujita K, Tanaka K.
    Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170
    [Abstract] [Full Text] [Related]

  • 7. [Survival, prognostic factors and modern tendencies in adjuvant treatment of diagnosed endometrial cancer patients with or without lymph node dissection].
    Ivanov I.
    Akush Ginekol (Sofiia); 2009 Aug; 48 Suppl 1():3-11. PubMed ID: 20387272
    [Abstract] [Full Text] [Related]

  • 8. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
    Alvarez Secord A, Havrilesky LJ, Bae-Jump V, Chin J, Calingaert B, Bland A, Rutledge TL, Berchuck A, Clarke-Pearson DL, Gehrig PA.
    Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
    [Abstract] [Full Text] [Related]

  • 9. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
    Hiura M, Nogawa T, Matsumoto T, Yokoyama T, Shiroyama Y, Wroblewski J.
    Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
    [Abstract] [Full Text] [Related]

  • 10. Para-aortic lymphadenectomy improves survival in patients with intermediate to high-risk endometrial carcinoma.
    Chang SJ, Kim WY, Yoon JH, Yoo SC, Chang KH, Ryu HS.
    Acta Obstet Gynecol Scand; 2008 Aug; 87(12):1361-9. PubMed ID: 18951214
    [Abstract] [Full Text] [Related]

  • 11. Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy.
    Watari H, Ohta Y, Hassan MK, Xiong Y, Tanaka S, Sakuragi N.
    Gynecol Oncol; 2008 Mar; 108(3):527-32. PubMed ID: 18177691
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer.
    Briët JM, Hollema H, Reesink N, Aalders JG, Mourits MJ, ten Hoor KA, Pras E, Boezen HM, van der Zee AG, Nijman HW.
    Gynecol Oncol; 2005 Mar; 96(3):799-804. PubMed ID: 15721428
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Multivariate analysis of prognostic factors in endometrial carcinoma].
    Li B, Wu LY, Li SM, Zhang WH, Zhang R, Ma SK.
    Ai Zheng; 2004 Sep; 23(9):1085-8. PubMed ID: 15363208
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.
    Hoekstra AV, Kim RJ, Small W, Rademaker AW, Helenowski IB, Singh DK, Schink JC, Lurain JR.
    Gynecol Oncol; 2009 Aug; 114(2):273-8. PubMed ID: 19428094
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers.
    Yokoyama Y, Maruyama H, Sato S, Saito Y.
    Gynecol Oncol; 1997 Mar; 64(3):411-7. PubMed ID: 9062142
    [Abstract] [Full Text] [Related]

  • 20. Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence.
    Fujimoto T, Nanjyo H, Fukuda J, Nakamura A, Mizunuma H, Yaegashi N, Sugiyama T, Kurachi H, Sato A, Tanaka T.
    Gynecol Oncol; 2009 Feb; 112(2):342-7. PubMed ID: 19062082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 211.